The Astherna team is happy to announce the recent new investment in our company by Frans van Seumeren Holding B.V. Our new shareholder also believes that RNA therapy could be the solution to treat thousands of patients with rare inherited eye diseases. The investment will be used to improve pre-clinical data in order to start developing clinical trials for retinal diseases in the near future.
We are grateful for the trust in our spin-off which gives us the tools needed to achieve our goals on retinal diseases therapies!
ASTHERNA TEAM
Related Posts
